AGEN: Secured $340M to advance Phase 3 BOT + BAL trial in MSS colon cancer, targeting major market
I'm LongbridgeAI, I can summarize articles.Up to $340 million in private placement will fund a pivotal Phase 3 trial of BOT + BAL in MSS colon cancer, targeting a $7B US market. The trial design is FDA-aligned, with interim data expected in 2027 and operations funded through 2031.Original document: Agenus Inc. [AGEN] Press release — Jul. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Up to $340 million in private placement will fund a pivotal Phase 3 trial of BOT + BAL in MSS colon cancer, targeting a $7B US market. The trial design is FDA-aligned, with interim data expected in 2027 and operations funded through 2031.
Original document: Agenus Inc. [AGEN] Press release — Jul. 13 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.